|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
|
|
3
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnson SW, Ozols RF and Hamilton TC:
Mechanisms of drug resistance in ovarian cancer. Cancer.
71:644–649. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Parikh A, Lee C, Peronne J, Marchini S,
Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F,
Mullokandov G, Fishman D, D’Incalci M, Rahaman J, Kalir T, Redline
RW, Brown BD, Narla G and DiFeo A: microRNA-181a has a critical
role in ovarian cancer progression through the regulation of the
epithelial-mesenchymal transition. Nat Commun. 5:29772014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li H, Xu H and Shen H: microRNA-106a
modulates cisplatin sensitivity by targeting PDCD4 in human ovarian
cancer cells. Oncol Lett. 7:183–188. 2014.PubMed/NCBI
|
|
8
|
Yin F, Liu X, Li D, Wang Q, Zhang W and Li
L: Tumor suppressor genes associated with drug resistance in
ovarian cancer (review). Oncol Rep. 30:3–10. 2013.PubMed/NCBI
|
|
9
|
Yin F, Liu X, Li D, Wang Q, Zhang W and Li
L: Bioinformatic analysis of chemokine (C-C motif) ligand 21 and
SPARC-like protein 1 revealing their associations with drug
resistance in ovarian cancer. Int J Oncol. 42:1305–1316.
2013.PubMed/NCBI
|
|
10
|
Oakley BR and Morris R: A mutation in
Aspergillus nidulans that blocks the transition from
interphase to prophase. J Cell Biol. 96:1155–1158. 1983.
|
|
11
|
Fry AM, O’Regan L, Sabir SR and Bayliss R:
Cell cycle regulation by the NEK family of protein kinases. J Cell
Sci. 125:4423–4433. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Malumbres M and Barbacid M: Cell cycle
kinases in cancer. Curr Opin Genet Dev. 17:60–65. 2007. View Article : Google Scholar
|
|
13
|
Bou Zgheib N, Xiong Y, Marchion DC, Bicaku
E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A and
Gonzalez-Bosquet J: The O-glycan pathway is associated with in
vitro sensitivity to gemcitabine and overall survival from ovarian
cancer. Int J Oncol. 41:179–188. 2012.PubMed/NCBI
|
|
14
|
Lee J and Gollahon L: Nek2-targeted ASO or
siRNA pretreatment enhances anticancer drug sensitivity in
triplenegative breast cancer cells. Int J Oncol. 42:839–847.
2013.PubMed/NCBI
|
|
15
|
Zhou W, Yang Y, Xia J, Wang H, Salama ME,
Xiong W, Xu H, Shetty S, Chen T and Zeng Z: NEK2 induces drug
resistance mainly through activation of efflux drug pumps and is
associated with poor prognosis in myeloma and other cancers. Cancer
Cell. 23:48–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De Angelis PM, Svendsrud DH, Kravik KL and
Stokke T: Cellular response to 5-fluorouracil (5-FU) in
5-FU-resistant colon cancer cell lines during treatment and
recovery. Mol Cancer. 5:202006.PubMed/NCBI
|
|
17
|
Doles J, Hemann MT, Doles J and Hemann M:
Nek4 status differentially alters sensitivity to distinct
microtubule poisons. Cancer Res. 70:10332010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Upregulation of NEK2 is associated with drug resistance in
ovarian cancer. Oncol Rep. 31:745–754. 2014.PubMed/NCBI
|
|
19
|
Hawkins SM, Loomans HA, Wan YW,
Ghosh-Choudhury T, Coffey D, Xiao W, Liu Z, Sangi-Haghpeykar H and
Anderson ML: Expression and functional pathway analysis of nuclear
receptor NR2F2 in ovarian cancer. J Clin Endocrinol Metab.
98:E1152–E1162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bani MR, Nicoletti MI, Alkharouf NW,
Ghilardi C, Petersen D, Erba E, Sausville EA, Liu ET and Giavazzi
R: Gene expression correlating with response to paclitaxel in
ovarian carcinoma xenografts. Mol Cancer Ther. 3:111–121. 2004.
|
|
21
|
Arora S, Bisanz KM, Peralta LA, Basu GD,
Choudhary A, Tibes R and Azorsa DO: RNAi screening of the kinome
identifies modulators of cisplatin response in ovarian cancer
cells. Gynecol Oncol. 118:220–227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Le XF, Hittelman WN, Liu J, McWatters A,
Li C, Mills GB and Bast RC Jr: Paclitaxel induces inactivation of
p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple
signaling pathways in mitosis. Oncogene. 22:484–497. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng L, Lu W, Kulkarni B, Pejovic T, Yan
X, Chiang JH, Hood L, Odunsi K and Lin B: Analysis of chemotherapy
response programs in ovarian cancers by the next-generation
sequencing technologies. Gynecol Oncol. 117:159–169. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bozic I, Antal T, Ohtsuki H, Carter H, Kim
D, Chen S, Karchin R, Kinzler KW, Vogelstein B and Nowak MA:
Accumulation of driver and passenger mutations during tumor
progression. Proc Natl Acad Sci USA. 107:18545–18550. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moniz L, Dutt P, Haider N and Stambolic V:
Nek family of kinases in cell cycle, checkpoint control and cancer.
Cell Div. 6:182011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kashuba V, Dmitriev AA, Krasnov GS,
Pavlova T, Ignatjev I, Gordiyuk VV, Gerashchenko AV, Braga EA,
Yenamandra SP, Lerman M, Senchenko VN and Zabarovsky E: NotI
microarrays: novel epigenetic markers for early detection and
prognosis of high grade serous ovarian cancer. Int J Mol Sci.
13:13352–13377. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: a cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barrett T and Edgar R: Mining microarray
data at NCBI’s Gene Expression Omnibus (GEO)*. Methods
Mol Biol. 338:175–190. 2006.
|
|
29
|
Edgar R, Domrachev M and Lash AE: Gene
Expression Omnibus: NCBI gene expression and hybridization array
data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mostafavi S, Ray D, Warde-Farley D,
Grouios C and Morris Q: GeneMANIA: a real-time multiple association
network integration algorithm for predicting gene function. Genome
Biol. 9(Suppl 1): S42008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Warde-Farley D, Donaldson SL, Comes O,
Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT,
Maitland A, Mostafavi S, Montojo J, Shao Q, Wright G, Bader GD and
Morris Q: The GeneMANIA prediction server: biological network
integration for gene prioritization and predicting gene function.
Nucleic Acids Res. 38:W214–W220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zuberi K, Franz M, Rodriguez H, Montojo J,
Lopes CT, Bader GD and Morris Q: GeneMANIA prediction server 2013
update. Nucleic Acids Res. 41:W115–W222. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kuhn M, Szklarczyk D, Franceschini A, von
Mering C, Jensen LJ and Bork P: STITCH 3: zooming in on
protein-chemical interactions. Nucleic Acids Res. 40:D876–D880.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kuhn M, Szklarczyk D, Franceschini A,
Campillos M, von Mering C, Jensen LJ, Beyer A and Bork P: STITCH 2:
an interaction network database for small molecules and proteins.
Nucleic Acids Res. 38:D552–D556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kuhn M, von Mering C, Campillos M, Jensen
LJ and Bork P: STITCH: interaction networks of chemicals and
proteins. Nucleic Acids Res. 36:D684–D688. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wishart DS, Knox C, Guo AC, Cheng D,
Shrivastava S, Tzur D, Gautam B and Hassanali M: DrugBank: a
knowledgebase for drugs, drug actions and drug targets. Nucleic
Acids Res. 36:D901–D906. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Law V, Knox C, Djoumbou Y, Jewison T, Guo
AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A,
Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y and Wishart DS:
DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids
Res. 42:D1091–D1097. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
de Leeuw N, Dijkhuizen T, Hehir-Kwa JY, et
al: Diagnostic interpretation of array data using public databases
and internet sources. Hum Mutat. 33:930–940. 2012.PubMed/NCBI
|
|
39
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk - database: prediction of possible miRNA binding sites by
‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847.
2011.
|
|
40
|
Li M, Balch C, Montgomery JS, Jeong M,
Chung JH, Yan P, Huang TH, Kim S and Nephew KP: Integrated analysis
of DNA methylation and gene expression reveals specific signaling
pathways associated with platinum resistance in ovarian cancer. BMC
Med Genomics. 2:342009. View Article : Google Scholar
|
|
41
|
Tang MK, Zhou HY, Yam JW and Wong AS:
c-Met overexpression contributes to the acquired apoptotic
resistance of nonadherent ovarian cancer cells through a cross talk
mediated by phosphatidylinositol 3-kinase and extracellular
signal-regulated kinase 1/2. Neoplasia. 12:128–138. 2010.
|
|
42
|
Pan B, Yao KS, Monia BP, Dean NM, McKay
RA, Hamilton TC and O’Dwyer PJ: Reversal of cisplatin resistance in
human ovarian cancer cell lines by a c-jun antisense
oligodeoxynucleotide (ISIS 10582): evidence for the role of
transcription factor overexpression in determining resistant
phenotype. Biochem Pharmacol. 63:1699–1707. 2002. View Article : Google Scholar
|
|
43
|
Mansouri A, Ridgway LD, Korapati AL, Zhang
Q, Tian L, Wang Y, Siddik ZH, Mills GB and Claret FX: Sustained
activation of JNK/p38 MAPK pathways in response to cisplatin leads
to Fas ligand induction and cell death in ovarian carcinoma cells.
J Biol Chem. 278:19245–19256. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Smith V, Hobbs S, Court W, Eccles S,
Workman P and Kelland LR: ErbB2 overexpression in an ovarian cancer
cell line confers sensitivity to the HSP90 inhibitor geldanamycin.
Anticancer Res. 22:1993–1999. 2002.PubMed/NCBI
|
|
45
|
Zhou BP, Hu MC, Miller SA, Yu Z, Xia W,
Lin SY and Hung MC: HER-2/neu blocks tumor necrosis factor-induced
apoptosis via the Akt/NF-kappaB pathway. J Biol Chem.
275:8027–8031. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qiu L, Di W, Jiang Q, Scheffler E, Derby
S, Yang J, Kouttab N, Wanebo H, Yan B and Wan Y: Targeted
inhibition of transient activation of the EGFR-mediated cell
survival pathway enhances paclitaxel-induced ovarian cancer cell
death. Int J Oncol. 27:1441–1448. 2005.PubMed/NCBI
|
|
47
|
Sen T, Sen N, Brait M, Begum S, Chatterjee
A, Hoque MO, Ratovitski E and Sidransky D: DeltaNp63alpha confers
tumor cell resistance to cisplatin through the AKT1 transcriptional
regulation. Cancer Res. 71:1167–1176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xing H, Weng D, Chen G, Tao W, Zhu T, Yang
X, Meng L, Wang S, Lu Y and Ma D: Activation of
fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by
regulating survivin protein expression in ovarian and breast cancer
cells. Cancer Lett. 261:108–119. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Weng D, Song X, Xing H, Ma X, Xia X, Weng
Y, Zhou J, Xu G, Meng L, Zhu T, Wang S and Ma D: Implication of the
Akt2/survivin pathway as a critical target in paclitaxel treatment
in human ovarian cancer cells. Cancer Lett. 273:257–265. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Guan H, Zhang H, Cai J, Wu J, Yuan J, Li
J, Huang Z and Li M: IKBKE is over-expressed in glioma and
contributes to resistance of glioma cells to apoptosis via
activating NF-κB. J Pathol. 223:436–445. 2011.PubMed/NCBI
|
|
51
|
Suzuki K, Kokuryo T, Senga T, Yokoyama Y,
Nagino M and Hamaguchi M: Novel combination treatment for
colorectal cancer using Nek2 siRNA and cisplatin. Cancer Sci.
101:1163–1169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang P, Gao W, Li H, Reed E and Chen F:
Inducible degradation of checkpoint kinase 2 links to
cisplatin-induced resistance in ovarian cancer cells. Biochem
Biophys Res Commun. 328:567–572. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu YY, Li L, Li DR, Zhang W and Wang Q:
Suppression of WWOX gene by RNA interference reverses platinum
resistance acquired in SKOV3/SB cells. Zhonghua Fu Chan Ke Za Zhi.
43:854–858. 2008.(In Chinese).
|
|
54
|
Yang D, Khan S, Sun Y, Hess K, Shmulevich
I, Sood AK and Zhang W: Association of BRCA1 and BRCA2 mutations
with survival, chemotherapy sensitivity, and gene mutator phenotype
in patients with ovarian cancer. JAMA. 306:1557–1565. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhou C, Smith JL and Liu J: Role of BRCA1
in cellular resistance to paclitaxel and ionizing radiation in an
ovarian cancer cell line carrying a defective BRCA1. Oncogene.
22:2396–2404. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lee S, Choi EJ, Jin C and Kim DH:
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA
amplification contributes to cisplatin resistance in an ovarian
cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wu H, Cao Y, Weng D, Xing H, Song X, Zhou
J, Xu G, Lu Y, Wang S and Ma D: Effect of tumor suppressor gene
PTEN on the resistance to cisplatin in human ovarian cancer cell
lines and related mechanisms. Cancer Lett. 271:260–271. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kawakami Y, Hama S, Hiura M, Nogawa T,
Chiba T, Yokoyama T, Takashima S, Tajiri H, Eguchi K, Nagai N,
Shigemasa K, Ohama K, Kurisu K and Heike Y: Adenovirus-mediated p16
gene transfer changes the sensitivity to taxanes and Vinca
alkaloids of human ovarian cancer cells. Anticancer Res.
21:2537–2545. 2001.PubMed/NCBI
|
|
59
|
Plumb JA, Strathdee G, Sludden J, Kaye SB
and Brown R: Reversal of drug resistance in human tumor xenografts
by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene
promoter. Cancer Res. 60:6039–6044. 2000.
|
|
60
|
Ratner ES, Keane FK, Lindner R, Tassi RA,
Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S,
Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S,
Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford
TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD and
Weidhaas JB: A KRAS variant is a biomarker of poor outcome,
platinum chemotherapy resistance and a potential target for therapy
in ovarian cancer. Oncogene. 31:4559–4566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Vogt U, Falkiewicz B, Bielawski K, Bosse U
and Schlotter CM: Relationship of c-myc and erbB oncogene family
gene aberrations and other selected factors to ex vivo
chemosensitivity of ovarian cancer in the modified
ATP-chemosensitivity assay. Acta Biochim Pol. 47:157–164.
2000.PubMed/NCBI
|
|
62
|
Bardella C, Dettori D, Olivero M, Coltella
N, Mazzone M and Di Renzo MF: The therapeutic potential of
hepatocyte growth factor to sensitize ovarian cancer cells to
cisplatin and paclitaxel in vivo. Clin Cancer Res. 13:2191–2198.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Xiao X, Melton DW and Gourley C: Mismatch
repair deficiency in ovarian cancer - molecular characteristics and
clinical implications. Gynecol Oncol. 132:506–512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gregory-Bass RC, Olatinwo M, Xu W,
Matthews R, Stiles JK, Thomas K, Liu D, Tsang B and Thompson WE:
Prohibitin silencing reverses stabilization of mitochondrial
integrity and chemoresistance in ovarian cancer cells by increasing
their sensitivity to apoptosis. Int J Cancer. 122:1923–1930. 2008.
View Article : Google Scholar
|
|
65
|
Sampson KE, Wolf CL and Abraham I:
Staurosporine reduces P-glycoprotein expression and modulates
multidrug resistance. Cancer Lett. 68:7–14. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gnoni A, Marech I, Silvestris N, Vacca A
and Lorusso V: Dasatinib: an anti-tumour agent via Src inhibition.
Curr Drug Targets. 12:563–578. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Jinawath N, Vasoontara C, Jinawath A, Fang
X, Zhao K, Yap KL, Guo T, Lee CS, Wang W, Balgley BM, Davidson B,
Wang TL and Shih Ie M: Oncoproteomic analysis reveals
co-upregulation of RELA and STAT5 in carboplatin resistant ovarian
carcinoma. PLoS One. 5:e111982010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Hirano G, Izumi H, Yasuniwa Y, Shimajiri
S, Ke-Yong W, Sasagiri Y, Kusaba H, Matsumoto K, Hasegawa T,
Akimoto M, Akashi K and Kohno K: Involvement of riboflavin kinase
expression in cellular sensitivity against cisplatin. Int J Oncol.
38:893–902. 2011.PubMed/NCBI
|
|
69
|
Hertzman Johansson C and Egyhazi Brage S:
BRAF inhibitors in cancer therapy. Pharmacol Ther. 142:176–182.
2014.
|
|
70
|
Bucheit AD and Davies MA: Emerging
insights into resistance to BRAF inhibitors in melanoma. Biochem
Pharmacol. 87:381–389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Janku F, Tsimberidou AM, Garrido-Laguna I,
Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW,
Piha-Paul SA, Wheler JJ, Moulder SL, Fu S and Kurzrock R: PIK3CA
mutations in patients with advanced cancers treated with
PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 10:558–565. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Janku F, Wheler JJ, Westin SN, Moulder SL,
Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna
I, Luthra R, Lee JJ, Lu KH and Kurzrock R: PI3K/AKT/mTOR inhibitors
in patients with breast and gynecologic malignancies harboring
PIK3CA mutations. J Clin Oncol. 30:777–782. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Fister S, Gunthert AR, Aicher B, Paulini
KW, Emons G and Grundker C: GnRH-II antagonists induce apoptosis in
human endometrial, ovarian, and breast cancer cells via activation
of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Cancer Res. 69:6473–6481. 2009. View Article : Google Scholar
|
|
74
|
Gene Ontology consortium. http://www.geneontology.org.
|
|
75
|
Gamberoni G, Storari S and Volinia S:
Finding biological process modifications in cancer tissues by
mining gene expression correlations. BMC Bioinformatics. 7:62006.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Lagreid A, Hvidsten TR, Midelfart H,
Komorowski J and Sandvik AK: Predicting gene ontology biological
process from temporal gene expression patterns. Genome Res.
13:965–979. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Tili E, Michaille JJ, Gandhi V, Plunkett
W, Sampath D and Calin GA: miRNAs and their potential for use
against cancer and other diseases. Future Oncol. 3:521–537. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Xie Z, Cao L and Zhang J: miR-21 modulates
paclitaxel sensitivity and hypoxia-inducible factor-1alpha
expression in human ovarian cancer cells. Oncol Lett. 6:795–800.
2013.PubMed/NCBI
|
|
81
|
Li B, Ren S, Li X, Wang Y, Garfield D,
Zhou S, Chen X, Su C, Chen M, Kuang P, Gao G, He Y, Fan L, Fei K,
Zhou C and Schmit-Bindert G: MiR-21 overexpression is associated
with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Lung Cancer. 83:146–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Yang SM, Huang C, Li XF, Yu MZ, He Y and
Li J: miR-21 confers cisplatin resistance in gastric cancer cells
by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Watson JA, Bryan K, Williams R, Popov S,
Vujanic G, Coulomb A, Boccon-Gibod L, Graf N, Pritchard-Jones K and
O’Sullivan M: miRNA profiles as a predictor of chemoresponsiveness
in Wilms’ tumor blastema. PLoS One. 8:e534172013.PubMed/NCBI
|
|
84
|
Berghmans T, Ameye L, Willems L, Paesmans
M, Mascaux C, Lafitte JJ, Meert AP, Scherpereel A, Cortot AB,
Cstoth I, Dernies T, Toussaint L, Leclercq N and Sculier JP:
Identification of microRNA-based signatures for response and
survival for non-small cell lung cancer treated with
cisplatin-vinorelbine A ELCWP prospective study. Lung Cancer.
82:340–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Korkmaz G, le Sage C, Tekirdag KA, Agami R
and Gozuacik D: miR-376b controls starvation and mTOR
inhibition-related autophagy by targeting ATG4C and BECN1.
Autophagy. 8:165–176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kong D, Ma S, Liang B, Yi H, Zhao Y, Xin
R, Cui L, Jia L and Liu X: The different regulatory effects of p53
status on multidrug resistance are determined by autophagy in
ovarian cancer cells. Biomed Pharmacother. 66:271–278. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hidaka H, Seki N, Yoshino H, Yamasaki T,
Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012.PubMed/NCBI
|
|
88
|
Wu J, Ji X, Zhu L, Jiang Q, Wen Z, Xu S,
Shao W, Cai J, Du Q, Zhu Y and Mao J: Up-regulation of
microRNA-1290 impairs cytokinesis and affects the reprogramming of
colon cancer cells. Cancer Lett. 329:155–163. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Yungang W, Xiaoyu L, Pang T, Wenming L and
Pan X: miR-370 targeted FoxM1 functions as a tumor suppressor in
laryngeal squamous cell carcinoma (LSCC). Biomed Pharmacother.
68:149–154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Fan C, Liu S, Zhao Y, Han Y, Yang L, Tao
G, Li Q and Zhang L: Upregulation of miR-370 contributes to the
progression of gastric carcinoma via suppression of FOXO1. Biomed
Pharmacother. 67:521–526. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Feng Y1, Wang L, Zeng J, Shen L, Liang X,
Yu H, Liu S, Liu Z, Sun Y, Li W, Chen C and Jia J: Fork head box M1
is overexpressed in Helicobacter pylori-induced gastric
carcinogenesis and is negatively regulated by hsa-miR-370. Mol
Cancer Res. 11:834–844. 2013.
|
|
92
|
Sharan R, Ulitsky I and Shamir R:
Network-based prediction of protein function. Mol Syst Biol.
3:882007. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Phuong T and Nhung N: Predicting gene
function using similarity learning. BMC Genomics. 14(Suppl 4):
S42013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Stuart JM, Segal E, Koller D and Kim SK: A
gene-coexpression network for global discovery of conserved genetic
modules. Science. 302:249–255. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Uetz P, Giot L, Cagney G, Mansfield TA,
Judson RS, Knight JR, Lockshon D, Narayan V, Srinivasan M, Pochart
P, Qureshi-Emili A, Li Y, Godwin B, Conover D, Kalbfleisch T,
Vijayadamodar G, Yang M, Johnston M, Fields S and Rothberg JM: A
comprehensive analysis of protein-protein interactions in
Saccharomyces cerevisiae. Nature. 403:623–627. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Janga S, Díaz-Mejía JJ and
Moreno-Hagelsieb G: Network-based function prediction and
interactomics: the case for metabolic enzymes. Metab Eng. 13:1–10.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Zeng X, Yin F, Liu X, Xu J, Xu Y, Huang J,
Nan Y and Qiu X: Upregulation of E2F transcription factor 3 is
associated with poor prognosis in hepatocellular carcinoma. Oncol
Rep. 31:1139–1146. 2014.PubMed/NCBI
|
|
98
|
Barrett T and Edgar R: Gene expression
omnibus: microarray data storage, submission, retrieval, and
analysis. Methods Enzymol. 411:352–369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Shah MA and Schwartz GK: Cell
cycle-mediated drug resistance: an emerging concept in cancer
therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI
|
|
100
|
Montopoli M, Ragazzi E, Froldi G and
Caparrotta L: Cell-cycle inhibition and apoptosis induced by
curcumin and cisplatin or oxaliplatin in human ovarian carcinoma
cells. Cell Prolif. 42:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wang X, Pan L, Mao N, Sun L, Qin X and Yin
J: Cell-cycle synchronization reverses Taxol resistance of human
ovarian cancer cell lines. Cancer Cell Int. 13:772013. View Article : Google Scholar : PubMed/NCBI
|
